COVID-19 vaccine, Novavax (2023-2024)
Generic name: COVID-19 Vaccine, Novavax (2023-2024)
Dosage form: intramuscular suspension (preservative-free 5 mcg/0.5 mL)
Drug class:
Viral vaccines
Usage of COVID-19 vaccine, Novavax (2023-2024)
COVID-19 is a serious disease caused by a coronavirus called SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). COVID-19 is spread from person to person through the air.
COVID-19 can affect your lungs or other organs. Symptoms may be mild or serious and include fever, chills, cough, sore throat, shortness of breath, tiredness, body aches, headache, loss of taste or smell, runny or stuffy nose, nausea, vomiting, or diarrhea.
The U.S. Food and Drug Administration (FDA) has authorized emergency use of this vaccine to prevent COVID-19. The Novavax COVID-19 vaccine is for use in people who are at least 12 years old.
COVID-19 vaccine does not contain coronavirus and cannot give you COVID-19. This vaccine will not treat an active COVID-19 infection.
Like any vaccine, COVID-19 vaccine may not provide protection in every person.
COVID-19 vaccine, Novavax (2023-2024) side effects
Get emergency medical help if you have signs of an allergic reaction: hives, itching, confusion, dizziness, fainting, vomiting, diarrhea, fast heartbeats, wheezing, difficult breathing, swelling of your face, lips, tongue, or throat.
An allergic reaction is more likely to occur within 30 minutes after you receive the vaccine. You will be treated quickly if you have a reaction.
You should not receive another dose if the first shot caused an allergic reaction. Your healthcare provider will determine if you can safely receive the second dose.
Becoming infected with COVID-19 is much more dangerous to your health than receiving this vaccine. Serious side effects other than an allergic reaction may include:
Fever may be a normal symptom as your body begins to develop immunity to COVID-19. However, you should call your doctor right away if you have any side effects that concern you.
Common side effects of COVID-19 vaccine, Novavax (2023-2024) may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1-800-822-7967.
You may also use a smartphone-based program called V-safe to communicate with the Centers for Disease Control and Prevention (CDC) about any health problems you have after receiving a COVID-19 vaccine: www.cdc.gov/vsafe.
Before taking COVID-19 vaccine, Novavax (2023-2024)
You should not receive this vaccine if you've ever had an allergic reaction to a Novavax COVID-19 vaccine.
Your healthcare provider will determine whether any reaction you have would prevent you from safely getting the second dose.
If you are infected with COVID-19, are waiting for testing results, or are exposed to someone infected with COVID-19: You may not be able to receive this vaccine until you have no symptoms and/or your required quarantine period has ended. Receiving this vaccine will not make you less contagious to other people if you are infected with COVID-19 but you have no symptoms.
Ask your doctor if you are unsure about any COVID-19 treatments you received.
Tell your vaccination provider if:
If you are pregnant, your name may be listed on a pregnancy registry to track the effects of this vaccine on the baby.
Tell your doctor if you are pregnant or breastfeeding.
Relate drugs
- Abrysvo
- ACAM2000
- Adenovirus vaccine, live
- Afluria
- Afluria 2015-2016 Formula
- Afluria PF Pediatric Quadrivalent 2021-2022 injection
- Afluria PF Quadrivalent 2021-2022 injection
- Afluria PF Quadrivalent 2022-2023 injection
- Afluria PF Quadrivalent 2023-2024 injection
- Afluria Quadrivalent 2021-2022 injection
- Afluria Quadrivalent 2022-2023 injection
- Afluria Quadrivalent 2023-2024 injection
- Agriflu
- Arexvy
- Attenuvax
- Audenz
- Comirnaty
- Comirnaty (2023-2024) PF (cvx 309) 2023-2024
- COVID-19 (12y+) vaccine Spikevax 2023-2024
- COVID-19 (12y+) vaccine, Pfizer 2023-2024
- COVID-19 (5y-11y) vaccine, Pfizer 2023-2024
- COVID-19 (6m-11y) vaccine, Moderna 2023-2024
- COVID-19 (6m-4y) vaccine, Pfizer 2023-2024
- COVID-19 vaccine, Novavax (2023-2024)
- Mumps virus vaccine, live
- Mumpsvax
- Cervarix
- Dengue tetravalent vaccine, live
- Dengue vaccine
- Dengvaxia
- Dryvax
- Engerix-B
- Engerix-B (HepB)
- Engerix-B Pediatric
- Fluad
- Fluad 2017-2018 Formula
- Fluad Quadrivalent PF 2022-2023 injection
- Fluad Quadrivalent PF 2023-2024 injection
- Fluarix PF Quadrivalent 2021-2022 injection
- Fluarix PF Quadrivalent 2022-2023 injection
- Fluarix PF Quadrivalent 2023-2024 injection
- Fluarix Quadrivalent
- Fluarix Quadrivalent 2013-2014 Formula
- Fluarix Quadrivalent 2015-2016 Formula
- Flublok 2015-2016 Formula
- Flublok 2016-2017 Formula
- Flublok 2017-2018 Formula
- Flublok Quadrivalent
- Flublok Quadrivalent 2016-2017 Formula
- Flublok Quadrivalent 2017-2018 Formula
- Flublok Quadrivalent 2021-2022 injection
- Flublok Quadrivalent 2022-2023 injection
- Flublok Quadrivalent 2023-2024 injection
- Flucelvax 2015-2016 Formula
- Flucelvax PF Quadrivalent 2021-2022 injection
- Flucelvax PF Quadrivalent 2022-2023 injection
- Flucelvax PF Quadrivalent 2023-2024 injection
- Flucelvax Quadrivalent
- Flucelvax Quadrivalent 2021-2022 injection
- Flucelvax Quadrivalent 2022-2023 injection
- Flucelvax Quadrivalent 2023-2024 injection
- FluLaval PF Quadrivalent 2021-2022 injection
- FluLaval PF Quadrivalent 2022-2023 injection
- FluLaval PF Quadrivalent 2023-2024 injection
- Flulaval Quadravalent 2013-2014 Season
- FluLaval Quadrivalent
- FluLaval Quadrivalent 2015-2016 Formula
- Flumist
- FluMist Quadrivalent 2015-2016 Formula
- FluMist Quadrivalent 2023-2024 nasal
- Fluvirin 2015-2016 Formula
- Fluzone 2013-2014 Formula
- Fluzone 2015-2016 Formula
- Fluzone High Dose 2015-2016 Formula
- Fluzone High-Dose Quadrivalent PF 2021-2022 injection
- Fluzone High-Dose Quadrivalent PF 2022-2023 injection
- Fluzone High-Dose Quadrivalent PF 2023-2024 injection
- Fluzone Intradermal Quadrivalent 2014-2015 Formula
- Fluzone Intradermal Quadrivalent 2015-2016 Formula
- Fluzone PF Pediatric Quadrivalent 2021-2022 injection
- Fluzone PF Quadrivalent 2021-2022 injection
- Fluzone PF Quadrivalent 2022-2023 injection
- Fluzone PF Quadrivalent 2023-2024 injection
- Fluzone Quadrivalent
- Fluzone Quadrivalent 2021-2022 injection
- Fluzone Quadrivalent 2022-2023 injection
- Fluzone Quadrivalent 2023-2024 injection
- Gardasil 9
- Gardasil 9 Vaccine
- Havrix
- Havrix Pediatric
- Hepatitis A adult vaccine
- Hepatitis A pediatric vaccine
- Hepatitis a vaccine
- Hepatitis B adult vaccine
- Hepatitis B pediatric vaccine
- Hepatitis b vaccine
- Hepatitis b vaccine recombinant, adjuvanted
- Heplisav-B
- Human papillomavirus (HPV) vaccine, 9-valent
- Human papillomavirus vaccine
- Imovax Rabies human diploid cell
- Influenza A (H1N1) 2009 Monovalent Vaccine
- Influenza a virus vaccine, h1n1, inactivated
- Influenza a virus vaccine, h5n1, adjuvanted
- Influenza virus vaccine
- Influenza virus vaccine injection
- Influenza virus vaccine nasal
- Influenza virus vaccine recombinant
- Influenza virus vaccine, adjuvanted
- Influenza Virus Vaccine, H5N1
- Influenza virus vaccine, live
- Ipol
- Ixiaro
- Janssen - Johnson & Johnson COVID-19 Vaccine
- Japanese encephalitis virus vaccine SA14-14-2
- Jynneos
- Measles virus vaccine, live
- Meruvax II
- Moderna COVID-19 (2023-2024) PF Vaccine (cvx 311) 2023-2024
- Moderna COVID-19 Vaccine
- Novavax COVID-19 (2023-2024) Vaccine,Adjuvanted PF (cvx 313)
- Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 308) 2023-2024
- Pfizer-BioNTech COVID-19 (2023-2024) Vaccine PF (cvx 310) 2023-2024
- Pfizer-BioNTech COVID-19 Vaccine
- Polio vaccine, inactivated
- Poliovirus vaccine, inactivated
- PreHevbrio
- RabAvert purified chick embryo cell
- Rabies vaccine human diploid cell
- Rabies vaccine purified chick embryo cell
- Recombivax HB
- Recombivax HB Adult
- Recombivax HB Dialysis Formulation
- Recombivax HB Pediatric/Adolescent
- Respiratory syncytial virus (RSV) vaccine
- Respiratory syncytial virus vaccine
- Respiratory syncytial virus vaccine, adjuvanted
- Rotarix
- Rotateq
- Rotavirus vaccine, live
- Rubella virus vaccine, live
- Sars-cov-2 (covid-19) vaccine, adenovirus 26 vector (janssen)
- Sars-cov-2 (covid-19) vaccine, mrna bivalent (moderna)
- Sars-cov-2 (covid-19) vaccine, mrna bivalent (pfizer)
- Sars-cov-2 (covid-19) vaccine, mrna-lnp, spike protein (moderna)
- Sars-cov-2 (covid-19) vaccine, protein subunit, adjuvanted (novavax)
- Shingrix
- Smallpox and monkeypox vaccine
- Smallpox monkeypox vaccine, live non-replicating
- Smallpox vaccine
- Spikevax
- Spikevax (2023-2024) PF (cvx 312) 2023-2024
- Tick-borne encephalitis pediatric vaccine
- Tick-borne encephalitis vaccine
- TicoVac
- TicoVac Pediatric
- Vaqta
- Vaqta Pediatric
- Varicella virus (chickenpox) vaccine
- Varicella virus vaccine, live
- Varivax
- Yellow fever vaccine
- YF-Vax
- Zostavax
- Zoster vaccine inactivated
- Zoster vaccine recombinant, adjuvanted
- Zoster vaccine, live
How to use COVID-19 vaccine, Novavax (2023-2024)
Usual Adult Dose for COVID-19:
FOR INVESTIGATIONAL USE ONLYPreviously vaccinated with any coronavirus disease 2019 (COVID-19) vaccine: 0.5 mL IM once, administered at least 2 months after the last dose of COVID-19 vaccineNo prior history of vaccination: 0.5 mL IM for 2 doses, administered 3 weeks apartComments:-This drug is not approved by the US FDA to prevent COVID-19. The US FDA has issued an Emergency Use Authorization (EUA) for the use of this drug to prevent COVID-19.-An additional dose administered at least 2 months following the last dose of this vaccine may be considered for patients who are severely immunocompromised (based on the healthcare provider's discretion).-No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.Use: For active immunization to prevent COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Usual Pediatric Dose for COVID-19:
FOR INVESTIGATIONAL USE ONLY12 years and older:-Previously vaccinated with any COVID-19 vaccine: 0.5 mL IM once, administered at least 2 months after the last dose of COVID-19 vaccine-No prior history of vaccination: 0.5 mL IM for 2 doses, administered 3 weeks apartComments:-This drug is not approved by the US FDA to prevent COVID-19. The US FDA has issued an EUA for the use of this drug to prevent COVID-19.-An additional dose administered at least 2 months following the last dose of this vaccine may be considered for patients who are severely immunocompromised (based on the healthcare provider's discretion).-No data are available regarding the use of this vaccine to complete a COVID-19 vaccine series initiated with another vaccine.Use: For active immunization to prevent COVID-19 due to SARS-CoV-2
Warnings
The U.S. Food and Drug Administration (FDA) has authorized emergency use of this vaccine to prevent COVID-19 in people 12 years and older. This vaccine has not been approved to treat COVID-19.
Becoming infected with COVID-19 is much more dangerous to your health than receiving this vaccine.
If you have a certain type of reaction after the first dose of this vaccine, your healthcare provider will determine if you can safely receive the second dose.
What other drugs will affect COVID-19 vaccine, Novavax (2023-2024)
Before receiving this vaccine, tell your vaccination provider about all other vaccines you have received. Other drugs may affect this vaccine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions